SREBF2 and metabolic dysfunction-associated steatotic liver disease: In our study, Lactobacillus oris treatment increased the expressions of both FXR and SREBP-2 in the liver of mice, suggesting that it might improve NAFLD through the FXR and SREBP pathways.